When outlining his complicated $30bn M&A transaction with Johnson & Johnson on Jan. 26, Jean-Paul Clozel reminisced on how close Actelion Pharmaceuticals Ltd. shareholders had come to exiting too early in 2011 when activist shareholder Elliott Advisors had tried to take control of the Swiss biotech at a much lower stock price.
Contrasting the agreed offer from J&J to pay $280 per share for Actelion – following weeks of exclusive talks –...








